LGD is a Biotech company focused on the research and use of nucleosides as therapeutics.
LGD Biotech offers expertise and support along the drug research and development process, from discovery to GMP industrialization of API candidates.
Our GLP (Good Laboratory Practice) facility performs quality controls at each step of API development, and carries out bioanalyses of preclinical and clinical samples from proof-of-concepts to phases 1 & 2 clinicals studies.
LGD collaborates intensively with universities, research institutes, industry partners and healthcare professionals.
One of our current topic of research is the use of NAD+ (Nicotinamide adenine dinucleotide ) booster molecules for therapeutics.
NAD+ is a redox coenzyme and a key co-factor for NAD+-dependent enzymes involved in cellular metabolism, stress resistance, DNA repair and longevity (Garrido and Djouder, 2017). Mounting evidences suggest that NAD+ levels decline with age and that its depletion associates with several hallmarks of aging and pathophysiological conditions (Lautrup et al., 2019; Verdin, 2015; Yoshino et al., 2018).
As such, the pharmacological increase of NAD+ levels in cells appears a promising strategy to treat diseases such as cancer, diabetes, neurodegeneration and inflammation (review covarrubias, DOI: 10.1038/s41580-020-00313-x).
